Identification of genetic and environmental suppressors of mitochondrial dysfunction
Identification of genetic and environmental suppressors of mitochondrial dysfunction
批准号:
10319607
负责人:
Joshua Daniel Meisel
金额:
$10.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-01 至 2023-03-31
关键词:
Acyl Carrier ProteinAffectAgingAlzheimer&aposs DiseaseAnabolismAnimalsBindingBiochemistryBioenergeticsBiogenesisBiological AssayBiologyBreathingBypassCaenorhabditis elegansCellsCellular biologyCollectionComplementComplexDNA sequencingDiseaseDisease modelDominant GenesElectrophoresisEnvironmentFerredoxinFriedreich AtaxiaFunctional disorderGene ExpressionGenesGeneticGenetic ModelsGenetic ScreeningGenetic TranscriptionGenomeGoalsHealthHereditary DiseaseHyperoxiaHypoxiaIn VitroIndividualInfant MortalityInner mitochondrial membraneIronLeadLeigh DiseaseLive BirthMeasurementMentorsMetabolicMetabolismMetalloproteasesMethylationMethyltransferaseMicroscopyMitochondriaMitochondrial DiseasesMolecularMolecular BiologyMusMutationNADHNADH dehydrogenase (ubiquinone)Nerve DegenerationNuclearNuclear RNAOrganismOxidative PhosphorylationOxygenOxygen ConsumptionPaperParkinson DiseasePatient-Focused OutcomesPhasePhysiologyPost-Transcriptional RNA ProcessingProteinsProteomeRNA StabilityRNA methylationRare DiseasesResearchSulfurSuppressor MutationsSystemTechniquesTherapeuticTracerTrainingTranslatingWorkcysteine desulfuraseeffective therapyexperimental studyfrataxingene synthesisgenetic analysisimprovedin vivoinsightmitochondrial dysfunctionmouse modelmutantnervous system disordernovelnovel therapeutic interventionpost-doctoral trainingpreventrare genetic disordersensorstable isotopetranscriptome sequencing
中文摘要
项目总结
英文摘要
Project Summary
Mitochondrial diseases, or inherited disorders of oxidative phosphorylation, can be caused by mutations in at
least 290 genes and affect approximately 1 in 5,000 live births. In addition to this collection of severe and
individually rare disorders, mitochondrial dysfunction may underly many common diseases of aging, such as
Parkinson’s and Alzheimer’s disease. The long-term goal of the applicant is to combine C. elegans genetics with
techniques of mitochondrial physiology, biochemistry, and metabolism to identify novel genetic and
environmental suppressors of mitochondrial dysfunction and elucidate the underlying mechanisms. Recent work
has shown that hypoxia may be an effective treatment for loss of Complex I of the electron transport chain,
however the precise molecular mechanism underlying the rescue by hypoxia remains elusive. In the first part of
his postdoctoral training, the applicant has demonstrated that hypoxia can rescue another mitochondrial disease,
Friedreich’s ataxia, which is caused by reduced levels of the Iron-Sulfur Cluster synthesis gene Frataxin. The
applicant has performed forward genetic screens in C. elegans and identified five novel genetic suppressors of
Frataxin and Complex I loss. In the K99/R00 application, the applicant proposes to (1) determine the mechanism
underlying Complex I rescue by hypoxia, and (2) characterize the novel genetic suppressors of Complex I and
Frataxin dysfunction. The applicant is jointly mentored by Drs. Gary Ruvkun and Vamsi Mootha in the MGH
Molecular Biology Department. The Ruvkun lab will provide an excellent environment for C. elegans genetic
analysis, and the Mootha lab will provide the candidate with new scientific training in mitochondrial physiology
(e.g. NADH and oxygen consumption assays), biochemistry (e.g. blue native page), and metabolism (e.g. stable
isotope tracer studies). In the K99 phase the applicant will also undertake coursework in Metabolism and
Biochemistry, complementing the new scientific skillsets learned in the Mootha lab, and allowing him to start an
independent research lab in the field of mitochondrial biology. Completion of the K99/R00 project will provide
insights into basic mitochondrial biology and may lead to novel therapeutic strategies for mitigating mitochondrial
disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金